

5/21-29/98

5/21 Purification of 1D3 B1 Monoclonal Antibody by Protein G Chromatography

In order to determine if the antibody produced by our 1D3 hybridoma is clonal for if the prep we isolated on the protein G column on 5/6 was contaminated with 33D1 antibody, we are purifying antibody from the supernatant of a limiting dilution clone of 1D3 - 1D3 B1. This way we will know that the hybridomas are clonal (so that the population of antibody being produced is clonal).

- Followed the procedure on pg. 35 except prior to using the column, I dropped it with 0.1M glycine pH 2.3 (as opposed to the regular pH 2.8 0.1M glycine) according to the recommendations of Pierce.

Started with 18 ml of hybridoma sup. Diluted 1:1 with binding buffer. Ran over equilibrated column over a 5 hour period. Eluted in 18 ml 0.1M glycine pH 2.8 - neutralized immediately w/ 25 μ l of 1M Tris pH 9 / 1 ml fraction.

Sample ID λ 280.0
1.5 \rightarrow Factor 1.000

| | Abs | Result mg/ml |
|--------------------|--------|-----------------|
| 1 | 0.0002 | 0.0002 |
| FR 1 | 0.0009 | 0.0009 |
| FR 2 | 0.1902 | 0.1902 |
| \rightarrow FR 3 | 0.6907 | 0.6907 |
| FR 4 | 0.2753 | 0.2753 |
| FR 5 | 0.1429 | 0.1429 |
| FR 6 | 0.0796 | 0.0796 |
| FR 7 | 0.0466 | 0.0466 |

E , extinction coefficient
for IgG = 1.5

$$E = \frac{Abs}{c} \times \text{path length}$$

$$\therefore c = \frac{Abs}{E}$$

$$\therefore \begin{aligned} \text{FR 2} &= 0.1268 \text{ mg/ml} \\ \text{FR 3} &= 0.460 \\ \text{FR 4} &= 0.184 \\ \text{FR 5} &= 0.095 \\ \text{FR 6} &= 0.053 \\ \text{FR 7} &= 0.031 \end{aligned}$$

0.950 mg/ml

$$\begin{aligned} \text{All are 1 ml fractions} \\ 0.950 \text{ mg} / 18 \text{ ml} &= 0.053 \text{ mg/ml} \\ &\text{or } 53 \mu\text{g/ml} \end{aligned}$$

This is likely near
the concentration

5/22 Silver Stain of Purified ID3 B1 Antibody

- 15% PAGE gel

- Samples:


| Lane | Sample | Quantity Loaded μ l | Estimated Quantity Loaded μ g (each protein) |
|------|---------------------|-------------------------|--|
| 1 | High MW markers | 1 μ l | 1 μ g (each protein) |
| 2 | Blank | | |
| 3 | Prep of 3/23 ID3 | 2.5 μ l | 0.675 μ g |
| 4 | " | 5 μ l | 1.35 μ g |
| 5 | " | 10 μ l | 2.7 μ g |
| 6 | Blank | | |
| 7 | Prep of 5/21 ID3 B1 | 1 μ l | 0.46 μ g |
| 8 | " | 2.5 μ l | 1.15 μ g |
| 9 | " | 5 μ l | 2.3 μ g |
| 10 | Blank | | |
| 11 | 33DI Ab | 1 μ l | 0.58 μ g |
| 12 | " | 2 μ l | 1.16 μ g |
| 13 | " | 4 μ l | 2.32 μ g |
| 14 | Blank | | |
| 15 | Blank | | |
| 16 | High MW markers | 1 μ l | 1 μ g (each protein) |

PREP 16N3
A280 = 210 μ g/ml

PREP 10N3
A280 = 46 μ g/ml

50 μ g/ml

photo taken on large eye - transilluminator



The prep #2 still looks contaminated with 33DI - but it's better - we'll go with it for the bioassay.

Our 2.5 μ l sample looks like the 33DI 2 μ l sample at 1.16 μ g
 \therefore estimated conc = $\frac{1.16 \mu\text{g}}{2.5 \mu\text{l}} = 0.464 \mu\text{g}/\mu\text{l}$ or 0.464 μ g/ml
 (464 μ g/ml)

5/29 BSA Assay to Determine Concentration of "Purified" ID3-B1 (mAb to STNER)

The A280's of the protein G column fractions seemed to be overestimated based on the bands I got when I loaded the SDS PAGE gel. Therefore, I will do a BSA Assay to more accurately determine the concentration of the "purified" ID3-B1 antibody prep that will be used in biological assays. We're most interested in fraction 3 because it appears to have the most Ab, but I'll throw in fractions 2 & 4 as a reference to compare to the A280 measurements.

- Enhanced protocol = 30 min at 60°C - microtiter plate
- Added 10 μ l of sample to 200 μ l of BSA reagent
- run in duplicate
- Blank = Tris/Glycine

BSA standard in μ g/ml

| POS | 1 | 2 | 3 | 4 |
|-----|-----------|-------|----------|-------|
| A | 0.144/100 | 0.138 | 0.197/12 | 0.196 |
| B | 0.258/100 | 0.239 | 0.097/12 | 0.098 |
| C | 0.374/30 | 0.330 | 0.576/12 | 0.562 |
| D | 0.440/40 | 0.461 | 0.383/12 | 0.378 |
| E | 0.577/20 | 0.533 | 0.135/12 | 0.131 |
| F | 0.676/10 | 0.608 | 0.750/12 | 0.736 |
| G | 0.748/10 | 0.712 | 0.116/12 | 0.121 |
| H | 0.0072 | 0.001 | | |

| Concentration | \bar{x} Absorbance |
|----------------|----------------------|
| 100 μ g/ml | 0.186 |
| 200 | 0.2485 |
| 300 | 0.327 |
| 400 | 0.4005 |
| 500 | 0.555 |
| 600 | 0.622 |
| 700 | 0.730 |

Regression Line:

$$y = 7.4571 \times 10^{-2} + 9.3107 \times 10^{-4} x$$

$$r^2 = 0.993$$

| | | ABS | | BSA conc est. | A280 conc est. |
|------------|-------|--------------------|--|----------------|----------------|
| Fraction 2 | N = | 0.0965 | | 131 μ g/ml | |
| | 1/2 = | 0.0975 x 2 = 0.195 | | 129 μ g/ml | 127 μ g/ml |
| Fraction 3 | N = | 0.5016 | | 528 μ g/ml | |
| | 1/2 = | 0.2805 x 2 = 0.561 | | 522 μ g/ml | 460 μ g/ml |
| | 1/4 = | 0.133 x 4 = 0.532 | | 491 μ g/ml | |
| Fraction 4 | N = | 0.243 | | 181 μ g/ml | |
| | 1/6 = | 0.145 x 3 = 0.435 | | 178 μ g/ml | 184 μ g/ml |

7/20/98 - 8/8/98

7/20 ID3 B1-4th Prep \Rightarrow Activities in TNF Bioassay.

Before we use this prep of ID3 B1 to inject mice in our immunotherapeutic experiments, we need to confirm that it neutralizes STNR binding to TNF. Therefore, we will re-run the bioassay of 6/5 (pg 63) on this prep, as well as the 5/21 that was used in the 6/5 bioassay.

Protocol - same as that on pg 63

Results:

There was no killing in any of the wells with TNF. On addition, the Actinomycin D did not seem to inhibit the growth of the cells such that the staining dropped by \sim half, which is typical. In fact, some of the wells with Actinomycin D showed more staining than with media alone.

Is there a problem with the cells, the Actinomycin, and/or the TNF?

Ryan will test our batch of Actinomycin D versus the batch I got from Mike using the lot of TNF released on 6/15/98. In addition, we will order some more TNF because the previous batch is about gone.

Ryan observed little inhibition of growth by the Actinomycin D and no killing w/ TNF. Is this due to the passage # of Clone K - we've never seen this before. It is likely not an inherent defect of the cells, because I saw the same inactivity on Clone 39 cells.

8/18 TNF Bioassay of $4/22$ + $7/10$ Preps of ID3 B1

We need to confirm the biological activity of ID3 B1 in neutralizing the binding of TNF to SMR.

same assay as on pg. 43

incubated plate w/ Act and TNF for 24 hours at 37°C

24 hour assay

| 7/10/98 Prep of ID3 B1 | | | | 0.1 μ g/ml Ab | | | 1 μ g/ml Ab | | | 10 μ g/ml Ab | | | | |
|------------------------|-------|--------|--------|-------------------|-------|-------|-----------------|-----------------|-------|------------------|-------|-------|-------|-------|
| | 1 | no Ab | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | |
| DMEM A | 0.003 | -0.004 | -0.001 | cells alone | 0.342 | 0.337 | 0.427 | cells + Act + D | 0.330 | 0.353 | 0.335 | 0.330 | 0.306 | 0.338 |
| TNF D B | 0.337 | 0.330 | 0.335 | 0.332 | 0.345 | 0.319 | 0.340 | 0.330 | 0.330 | 0.330 | 0.330 | 0.306 | 0.338 | |
| 6.25 D | 0.317 | 0.298 | 0.330 | 0.305 | 0.304 | 0.307 | 0.299 | 0.307 | 0.285 | 0.306 | 0.307 | 0.307 | 0.332 | |
| 12.5 D | 0.303 | 0.321 | 0.327 | 0.334 | 0.294 | 0.315 | 0.318 | 0.309 | 0.302 | 0.272 | 0.290 | 0.328 | | |
| 25 F | 0.297 | 0.307 | 0.297 | 0.298 | 0.306 | 0.313 | 0.280 | 0.297 | 0.304 | 0.297 | 0.294 | 0.324 | | |
| 50 F | 0.297 | 0.297 | 0.304 | 0.298 | 0.311 | 0.301 | 0.301 | 0.284 | 0.273 | 0.288 | 0.245 | 0.258 | | |
| 100 B | 0.280 | 0.290 | 0.244 | 0.289 | 0.285 | 0.291 | 0.281 | 0.298 | 0.285 | 0.280 | 0.242 | 0.317 | | |
| H | 0.274 | 0.277 | 0.270 | 0.270 | 0.278 | 0.274 | 0.265 | 0.254 | 0.279 | 0.274 | 0.244 | 0.277 | | |

* Again, there is no difference between "Cells alone" and "Cells + Actinomycin D". Either the cells are resistant to Actinomycin, or the Actinomycin has gone bad. Decided to incubate the plate an additional 12 hours to determine if the Actinomycin D is active.

Actinomycin D is active

24 hour assay

| 8/22/98 Prep of ID3 B1 | | | | 0.1 μ g/ml Ab | | | 1 μ g/ml Ab | | | 10 μ g/ml Ab | | |
|------------------------|-------|--------|-------|-------------------|-------|-------|-----------------|-------|-------|------------------|-------|-------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| DMEM A | 0.003 | -0.004 | 0.000 | cells alone | | | cells + Act | | | 0.184 | 0.227 | 0.114 |
| TNF D B | 0.242 | 0.235 | 0.245 | 0.228 | 0.232 | 0.234 | 0.234 | 0.229 | 0.235 | 0.224 | 0.244 | 0.230 |
| 6.25 D | 0.187 | 0.214 | 0.218 | 0.207 | 0.207 | 0.201 | 0.209 | 0.205 | 0.214 | 0.220 | 0.214 | 0.241 |
| 12.5 D | 0.212 | 0.205 | 0.213 | 0.200 | 0.213 | 0.212 | 0.207 | 0.216 | 0.207 | 0.215 | 0.204 | 0.188 |
| 25 F | 0.193 | 0.194 | 0.207 | 0.205 | 0.195 | 0.207 | 0.200 | 0.207 | 0.194 | 0.202 | 0.207 | 0.202 |
| 50 F | 0.183 | 0.177 | 0.190 | 0.184 | 0.195 | 0.204 | 0.203 | 0.200 | 0.191 | 0.218 | 0.193 | 0.190 |
| 100 B | 0.168 | 0.172 | 0.180 | 0.175 | 0.170 | 0.182 | 0.179 | 0.187 | 0.177 | 0.189 | 0.197 | 0.194 |
| H | 0.174 | 0.178 | 0.174 | 0.181 | 0.174 | 0.175 | 0.180 | 0.177 | 0.180 | 0.171 | 0.169 | 0.170 |

The Actinomycin D does appear to be active: Cells alone = 0.536
Cells + Act = 0.229 (43% inhibition) We are not, however, observing much killing with TNF: no antibody data

10 μ g/ml Ab data
 $0 = 0.241 = 15\%$
 $6.25 = 0.206 = 13\%$
 $12.5 = 0.216 = 17\%$
 $25 = 0.199 = 24\%$
 $50 = 0.182 = 28\%$
 $100 = 0.173 = 28\%$

10 μ g/ml Ab data
 $0 = 0.233 = 3\%$
 $6.25 = 0.228 = 13\%$
 $12.5 = 0.223 = 18\%$
 $25 = 0.203 = 42\%$
 $50 = 0.200 = 42\%$
 $100 = 0.193 = 17\%$

maybe we should extend the incubation period - go back to original protocol for next + maybe do a 48h assay with Act + TNF

11/23/98

DISSERTATION

**THE ROLE OF SOLUBLE TUMOR NECROSIS
FACTOR RECEPTOR TYPE I
IN TUMOR SURVIVAL**

Submitted by

Cheryl Lynn Selinsky

Department of Microbiology

In partial fulfillment of the requirements

for the Degree of Doctor of Philosophy

Colorado State University

Fort Collins, Colorado

Spring 1999